Oppenheimer Maintains Outperform Rating on Nurix Therapeutics, $32 Target
Oppenheimer maintained its Outperform rating on Nurix Therapeutics with a $32.00 price target, implying 44.4% upside from the Oct. 12 close of $22.16.
Story updates
01:36:33 PM UTC
SquawkNews
Ratings actions from Benzinga: GMT) Nurix Therapeutics Price Target Raised to $32.00/Share From $28.00 by OppenheimerRatings actions from Benzinga